Only in Titles

Search results for: Histamine

paperclip

#39508246   2024/11/06 To Up

The association between metabolite profiles and impaired bone microstructure in adult growth hormone deficient rats.

Adult growth hormone deficiency (AGHD) is associated with an increased risk of fractures and impaired bone microstructure. Understanding the metabolic changes accompanying bone deterioration in AGHD might provide insights into mechanisms behind molecular changes and develop new biomarkers or nutritional strategies for bone destruction. Our study aimed to investigate the association between altered metabolite patterns and impaired bone microstructure in adult rats with growth hormone deficiency.
Xiaonan Guo, Shanshan Liu, Wenjing Hu, Xiaorui Lyu, Hanyuan Xu, Huijuan Zhu, Hui Pan, Linjie Wang, Yu Wan, Hongbo Yang, Fengying Gong

2642 related Products with: The association between metabolite profiles and impaired bone microstructure in adult growth hormone deficient rats.

96/kit100 μg20ug100.00 ug1 mg50 μgProtein96 tests96 wells (1 kit)

Related Pathways

paperclip

#39504861   2024/11/02 To Up

Ion-exchange chromatography in the assessment of environmental pollution with chlortetracycline.

Chemical substances such as drugs pose a threat to the environment. One of the substances recorded in soil and water is chlortetracycline, an antibiotic used in veterinary medicine. Plants exposed to such xenobiotics show changes in the content of biogenic amines. An analytical technique - ion exchange chromatography is used to assess their content. The occurrence of these active compounds is used to determine the degree of environmental pollution with chemical substances. The study aimed to evaluate the toxicity of chlortetracycline (CTC) at concentrations of 0; 0.05; 0.1; 0.2 0.5;1; 2; 3; and 5 mM towards the test organism Lemna minor, and determine the content of biogenic amines in the plant tissues. The content of biogenic amines was analyzed by ion-exchange chromatography with post-column ninhydrin derivatization and photometric detection. The Lemna test proved that increasing concentrations of CTC had a toxic effect on the plants. It was calculated that the Lowest Observed Effects Concentration (LOEC) of CTC at >0.04 mM and >0.05 mM was phytotoxic to L. minor growth and yield. It was determined that the levels of histamine, tyramine, and cadaverine exhibited an increase, reaching 1.04, 1.90, and 3.10 µg g of tissue at 2.00 mM CTC. Simultaneously, spermine and putrescine increased to 1.21 and 3.89 µg g of tissue at concentrations of 0.10 and 0.50 mM of the drug. Conversely, the study revealed an over 88 % reduction in spermidine in plants at 5 mM of CTC. Using ion-exchange chromatography, analysis of biogenic amines, particularly spermidine and cadaverine, highlighted these intra-tissue compounds as sensitive biomarkers for water contamination with the tested drug. This research confirmed that the Lemna test is effective for assessing CTC toxicity and that ion-exchange chromatography is useful for evaluating environmental pollution by this antibiotic.
Łukasz Sikorski, Agnieszka Bęś, Elżbieta Karetko-Sikorska, Wojciech Truszkowski, Katarzyna Tomaszewska

2401 related Products with: Ion-exchange chromatography in the assessment of environmental pollution with chlortetracycline.

1100 μg

Related Pathways

paperclip

#39504659   2024/11/04 To Up

Neuropeptide FF prevented histamine- or chloroquine-induced acute itch behavior through non-NPFF receptors mechanism in male mice.

The neuropeptide FF (NPFF) system regulates various physiological and pharmacological functions, particularly pain modulation. However, the modulatory effect of NPFF system on itch remains unclear. To investigate the modulatory effect and functional mechanism induced by NPFF system on acute itch, we examined the effects of supraspinal administration of NPFF and related peptides on acute itch induced by intradermal (i.d.) injection of histamine or chloroquine in male mice. Our results indicated that intracerebroventricular (i.c.v.) administration of NPFF dose-dependently prevented histamine- or chloroquine-induced acute itch behaviors. In addition, the modulatory effect of NPFF was not affected by the selective NPFF receptor antagonist RF9. Furthermore, we investigated the effects of NPVF and dNPA, the selective agonists of NPFF and NPFF receptors respectively, on the acute itch. The results demonstrated that both NPFF agonists effectively prevented acute itch induced by histamine or chloroquine in a manner similar to NPFF, and their effects were also not modified by RF9. To further investigate the possible mechanism of the NPFF receptors agonists, the NPFF-derived analogues [Phg]-NPFF and NPFF(1-7)-NH that could not activate NPFF receptors in cAMP assays were subsequently tested in the acute itch model. Interestingly, [Phg]-NPFF, but not NPFF(1-7)-NH, prevented acute itch behavior after i.c.v. administration. In conclusion, our findings reveal that NPFF and related peptides prevent histamine- and chloroquine-induced acute itch through a NPFF receptor-independent mechanism. And it was revealed that the C-terminal phenyl structure of NPFF may play a crucial role in these modulatory effects on acute itch.
Honghai Tang, Ting Zhang, Jiamin Feng, Mengna Zhang, Biao Xu, Qinqin Zhang, Ning Li, Nan Zhang, Quan Fang

2790 related Products with: Neuropeptide FF prevented histamine- or chloroquine-induced acute itch behavior through non-NPFF receptors mechanism in male mice.

100 ug10mg10mg20mg100 μg10mg10mg5mg

Related Pathways

paperclip

#39504585   2024/10/30 To Up

Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist: Results from the phase 2 double-blind randomized placebo-controlled study for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.

Narcolepsy is a rare, chronic neurological disorder characterized by a dysregulated sleep-wake cycle, with core clinical features including excessive daytime sleepiness (EDS), cataplexy, hypnopompic/hypnagogic hallucinations, and sleep paralysis. Several treatment options are available for the symptomatic management of narcolepsy, but they have limitations. Comorbidities of narcolepsy further limit the treatment choices. Blocking of histamine 3 (H3) receptors has been demonstrated to be a viable approach for the management of symptoms of narcolepsy. Samelisant (SUVN-G3031) is a new H3 receptor inverse agonist. The efficacy, safety, tolerability, and pharmacokinetics of Samelisant in narcolepsy patients were evaluated in a phase 2, double-blind, placebo-controlled study (ClinicalTrials.gov identifier: NCT04072380). Patients diagnosed with narcolepsy according to the International Classification of Sleep Disorders criteria and having an Epworth Sleepiness Scale (ESS) score of ≥12 and a mean Maintenance of Wakefulness Test (MWT) time of <12 min across the 4 sessions at baseline were enrolled. The total study duration was up to 7 weeks, which included a screening period of 4 weeks, a treatment period of 2 weeks, and a safety follow-up 1 week after the last study drug administration. The primary efficacy measure was the change in total ESS score compared to placebo. Secondary and exploratory assessments included the Clinical Global Impression of Severity, MWT, Clinical Global Impression of Change, Patient Global Impression of Change and cataplexy rate. Safety assessments included monitoring adverse events (AEs) and laboratory assessments. Of the 426 patients screened, 190 were randomized. The safety and intention-to-treat population included 188 and 164 patients, respectively. A statistically significant treatment effect of Samelisant was observed on the primary endpoint, indicating improvements in EDS. The treatment's impact on EDS was also evident on the other patients' and clinicians' perspectives scales. The AEs reported in ≥5 % patients in any treatment groups were insomnia, abnormal dreams, nausea, and hot flush. Global phase 3 studies and long-term safety and efficacy assessments of Samelisant are planned to reaffirm the current findings.
Ramakrishna Nirogi, Anil Shinde, Vinod Kumar Goyal, Jyothsna Ravula, Vijay Benade, Satish Jetta, Santosh Kumar Pandey, Ramkumar Subramanian, Veera Raghava Chowdary Palacharla, Abdul Rasheed Mohammed, Renny Abraham, Dhanunjay Kumar Dogiparti, Ilayaraja Kalaikadhiban, Pradeep Jayarajan, Venkat Jasti, Richard K Bogan

1554 related Products with: Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist: Results from the phase 2 double-blind randomized placebo-controlled study for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.

200ul1100 μg

Related Pathways

paperclip

#39503620   2024/11/06 To Up

Evaluating Vonoprazan for the treatment of erosive GERD and heartburn associated with GERD in adults.

Gastroesophageal reflux disease (GERD) is a common debilitating chronic disease presenting in two main forms based on esophageal mucosal appearance, the erosive reflux disease (ERD) and the non-erosive reflux disease (NERD). Acid secretion is a key factor in the disease pathogenesis and management. Potent acid-suppressant drugs have been manufactured since the mid of 1970s, initially with histamine-H2-receptors antagonists, and later, inhibitors of the proton pump (H+-K+-ATPase). More recently, potassium-competitive acid blockers (P-CABs), particularly Vonoprazan, have been introduced. Vonoprazan has shown high efficacy and safety profiles and exhibits several advantages that allow to overcome shortcomings of proton pump inhibitors (PPIs).
Elisa Marabotto, Francesco Calabrese, Andrea Pasta, Pierfrancesco Visaggi, Nicola de Bortoli, Amir Mari, Salvatore Tolone, Matteo Ghisa, Luisa Bertin, Vincenzo Savarino, Edoardo Vincenzo Savarino

2942 related Products with: Evaluating Vonoprazan for the treatment of erosive GERD and heartburn associated with GERD in adults.

250 mg 1 G 1 G1 5 G

Related Pathways

paperclip

#39503414   2024/11/06 To Up

Enhancing immuno-oncology efficacy with H1-antihistamine in cancer therapy: a review of current research and findings.

Cancer remains a major global cause of death, posing significant treatment challenges. The interactions between tumor cells and the tumor microenvironment (TME) are crucial in influencing tumor initiation, progression, metastasis, and treatment response. There has been significant research and clinical interest in targeting the TME as a therapeutic approach in cancer, with advancements being made through drug development. Histamine binds to HRH1 receptors on the TME, which inhibit CD8+ T cell activity, promote tumor growth, and contribute to resistance against immunotherapy. By inhibiting CD8+ T cells, the effectiveness of immunotherapies targeting these cells is reduced. By blocking the HRH1 pathway, H1-antihistamines can mitigate this suppression and enhance the response to immunotherapies that target CD8+ T cells. Therefore, understanding the role of histamine and its potential impact on T cells and the role of H1-antihistamines in improving immune-oncology (I/O) agents' efficacy ultimately could lead to more effective cancer therapies. The objective of this review is to examine the current literature to investigate the potential role of H1-antihistamines on the effectiveness of I/O drugs and their role in enhancing treatment against cancer. We conducted a comprehensive literature search, which included multiple databases including PubMed, Google Scholar, and EMBASE, as well as a search of oncology congresses. Our literature review initially identified thirty studies. Twenty-three of these were excluded for failing to meet inclusion criteria, which varied from study design to the type of antihistamines and patient populations involved. The clinical studies investigated the effect of different generations of H1-antihistamines in combination with I/O treatments on patients' outcomes. The findings from these studies indicated that patients using H1-antihistamines concomitantly with I/O agents experienced longer median overall survival (mOS), progression-free survival (mPFS), or improved survival compared to those who did not use antihistamines. Additionally, these trials differentiated between cationic and non-cationic H1-antihistamines, revealing that users of cationic antihistamines had overal better outcomes in terms of longer mOS and mPFS. The assessed trials were consistent in their comparisons of quantitative and qualitative, efficacy, and safety outcomes.
Oday Hamid, Negar Hamidi

2867 related Products with: Enhancing immuno-oncology efficacy with H1-antihistamine in cancer therapy: a review of current research and findings.



Related Pathways

paperclip

#39502691   2024/10/21 To Up

Histamine and Th2 cytokines independently and synergistically upregulate MMP12 expression in human M2 macrophages.

Beyond Th2 cells and various immune cells, M2 macrophages have been identified in lesional skin of atopic dermatitis (AD) indicating their involvement in the disease's underlying mechanisms. MMP12, a matrix-degrading enzyme, which is predominantly produced by macrophages, is increased in skin lesions of AD patients. In this study we investigated the expression of MMP12 mRNA in lesional AD skin at single cell level through RNA sequencing (scRNA-seq) and the expression of MMP12 in M2 macrophages from healthy individuals and AD patients in response to Th2 cytokines and histamine using quantitative PCR and ELISA. Additionally, we analyzed macrophages from dupilumab-treated AD patients using the same methods to assess the influence of Th2 cytokines on MMP12 expression . ScRNA-seq identified macrophages as the primary producers of MMP12 in lesional AD skin. , both MMP12 mRNA and protein expression were significantly increased in monocytes during differentiation to M2 macrophages in the presence of histamine, of Th2 cytokines or of Th2 cytokines in combination with histamine. In M2 macrophages obtained from dupilumab-treated AD patients, the upregulation of MMP12 expression by IL-4 and IL-13 was attenuated. Our findings unveil a novel mechanism whereby Th2 cytokines and histamine regulate MMP12 expression, potentially impacting skin barrier homeostasis in AD.
Alice Pereira da Fonseca, Stephan Traidl, Ralf Gutzmer, Katrin Schaper-Gerhardt, Thomas Werfel, Susanne Mommert

1578 related Products with: Histamine and Th2 cytokines independently and synergistically upregulate MMP12 expression in human M2 macrophages.

1000 0.1 mg16 Arrays/Slide100 1 ml16 Arrays/Slide100 μg16 Arrays/Slide200 100ul100 μg

Related Pathways

paperclip

#39497323   2024/11/04 To Up

Population pharmacokinetic modelling of cetirizine concentrations in human breast milk-A contribution from the ConcePTION project.

Cetirizine is an antihistamine commonly used to treat allergic rhinitis and other allergic conditions. Cetirizine is often prescribed to breastfeeding mothers although there is limited information on infant exposure via breast milk. The aim of this study was to develop a popPK model based on data from a lactation study to predict cetirizine breast milk concentrations and estimate the relative infant dose (RID) in a breastfed infant. A popPK model was developed in NONMEM on data from a human lactation study including 35 women using cetirizine or levocetirizine while breastfeeding. Serial samples of breast milk were collected (n = 205) and the cetirizine concentrations quantified using a validated LC-MS/MS method. A one-compartment model of cetirizine in breast milk was developed and employed to calculate the relative infant dose (RID). Covariates related to the maternal characteristics and breastfeeding patterns were evaluated in the model; only milk sampling pumping duration was found to be a significant covariate, with an increasing pumping duration leading to an increased apparent milk volume of distribution (V). The mean RID was 1.99% with the highest RID being 3.36% at C. PopPK modelling could be used to estimate infant exposure to cetirizine via breast milk. The low predicted exposure in infants supports that cetirizine is compatible with breastfeeding.
Erik Melander, Elisabet I Nielsen, Annika Lindqvist, Markus Hovd, Peggy Gandia, Alice Panchaud, Monia Guidi, Pieter Annaert, Pawel Baranczewski, Olav Spigset, Hedvig Nordeng

2672 related Products with: Population pharmacokinetic modelling of cetirizine concentrations in human breast milk-A contribution from the ConcePTION project.

100 μg100 μg100 μg100 μg100 μg1 mg100 100 μg

Related Pathways

paperclip

#39495351   2024/11/04 To Up

Sea Buckthorn Flavonoid Extracted with High Hydrostatic Pressure Alleviated Shrimp Allergy in Mice through the Microbiota and Metabolism.

Sea buckthorn ( L.) known as the deciduous shrub has been reported to have effects of antioxidant, anti-inflammatory, and immunomodulatory activities. Tropomyosin (TM) induced a regulatory immune response associated with food allergy. In this study, a mouse model of food allergy sensitized to tropomyosin (TM) was established to assess the antiallergic properties of sea buckthorn flavonoid extract (SBF). SBF alleviated mice's allergic symptoms and exhibited a significant reduction in the levels of IgE and histamine. Meanwhile, SBF repaired the allergic Th2 cell overpolarization generated by TM, via downregulating the IL-4 production and upregulating IFN-γ production to restore the balance of Th1/Th2 cells. Furthermore, the 16S RNA analysis showed that SBF primarily restored the gut microbiota via increasing the abundance in and decreasing in , and . Gut metabolomes determined by liquid chromatography-mass spectrometry (LC-MS) suggested that TM upregulated PE (14:0/22:1(13Z)) and SBF decreased formimino-l-glutamic acid and urocanic acid levels. According to the KEGG pathway analysis, SBF treatment has been shown to modulate glycerophospholipid and histidine metabolism to improve allergic reactions. SBF holds great promise as a novel potential agent for the treatment of food allergies.
Xiaoping Feng, Zhuomin Yan, Xiaojing Ren, Yining Jia, Jiao Sun, Jing Guo, Zhenpeng Gao, Huzhong Li, Fangyu Long

2853 related Products with: Sea Buckthorn Flavonoid Extracted with High Hydrostatic Pressure Alleviated Shrimp Allergy in Mice through the Microbiota and Metabolism.

4 Membranes/Box2 Pieces/Box4 Membranes/Box4 Arrays/Slide4 Arrays/Slide2 Pieces/Box4 Membranes/Box2 Pieces/Box4 Arrays/Slide

Related Pathways

paperclip

#39493768   2024/10/18 To Up

Pharmacological blockade of the mast cell MRGPRX2 receptor supports investigation of its relevance in skin disorders.

Because MRGPRX2 is now recognized as the mast cell receptor for basic secretagogues, there is currently a tremendous interest in whether MRGRPX2 could play an important role in various pruritic dermatoses such as chronic spontaneous urticaria. Therefore, we sought to identify new potent and selective antagonists to pharmacologically characterize the biological role of MRGPRX2.
Colin H Macphee, Xinzhong Dong, Qi Peng, Daniel V Paone, Per Stahl Skov, Katrine Baumann, Theresa Roethke, Deborah A Goldspink, Samuel K Pearson, Zining Wu

1684 related Products with: Pharmacological blockade of the mast cell MRGPRX2 receptor supports investigation of its relevance in skin disorders.

2 Pieces/Box100 μg8 inhibitors100ug100ug96 assays

Related Pathways